AstraZeneca's Imfinzi (durvalumab) plus chemotherapy, has gained CHMP recommendation for approval in the EU to treat NSCLC.

Vertex Pharma receives CHMP positive opinion for label expansion of Kaftrio in combination with ivacaftor: London Tuesday, March 4, 2025, 14:00 Hrs [IST] Vertex Pharmaceuticals, a ...

The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and ...